Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53-SLP vaccine with imiquimod or interferon-alfa in treated colorectal cancer
2008-004611-35Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2008
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of p53 synthetic long peptide vaccine, imiquimod and interferon alfa in colorectal cancer (CRC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Safety and Immunogenicity. Started Jul 2008; status: active.
02
Drugs
p53 synthetic long peptide vaccineimiquimodinterferon alfa
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-004611-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004611-35.